ABSTRACT
The effectiveness of treatment of anxiety-depressive syndrome with cymbalta, the selective inhibitor of serotonin and noradrenalin reuptake, has been assessed in 35 patients with discirculatory encephalopathy (mean age 50.9+/-1.78 years). Patients received cymbalta in dosage 60 mg daily during 2 months. Therapeutic efficacy was analyzed with a complaint questionnaire, depression scales (CES-D, Beck, Zung), the Spielberger's anxiety scale in the modification of Khanin, the Luescher color test and a battery of tests for assessment of cognitive processes. The statistically significant decrease of complaint frequency, intensity of depression, regardless of its baseline severity, and anxiety level was observed to the end of treatment course. The cognitive tests revealed the marked improvement of sustained attention functions and related with them short-term and working memory. Tolerability of the drug was rated as excellent, good and fair was reported by 90.6% of patients and 91.9% of physicians. The drug may be considered safety and effective for basic pharmacotherapy of affective and concomitant cognitive disorders of vascular genesis.
